CONDYLOX Drug Patent Profile

Which patents cover Condylox, and what generic alternatives are available?

Condylox is a drug marketed by Allergan and Teva Branded Pharm and is included in two NDAs.

The generic ingredient in CONDYLOX is podofilox. There are two drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the podofilox profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Condylox

A generic version of CONDYLOX was approved as podofilox by PADAGIS US on January 29^th, 2002.

Summary for CONDYLOX

US Patents:	0
Applicants:	2
NDAs:	2

US Patents and Regulatory Information for CONDYLOX

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Allergan	CONDYLOX	podofilox	GEL;TOPICAL	020529-001	Mar 13, 1997		DISCN	Yes	No
Teva Branded Pharm	CONDYLOX	podofilox	SOLUTION;TOPICAL	019795-001	Dec 13, 1990	AT	RX	Yes	Yes

International Patents for CONDYLOX

See the table below for patents covering CONDYLOX around the world.

Country	Patent Number	Title	Estimated Expiration
Norway	164658
Germany	3574595
Austria	48427
Denmark	169385

CONDYLOX Market Analysis and Financial Projection

Last updated: February 12, 2026

What is the current regulatory and market status of CONDYLOX?

CONDYLOX is a topical medication approved primarily for the treatment of external genital warts caused by human papillomavirus (HPV). It is marketed by GlaxoSmithKline (GSK) under the brand name CONDYLOX. The drug’s core active ingredient is podophyllotoxin, which has been used in clinical settings for decades.

CONDYLOX holds regulatory approval in multiple regions, including the US (FDA), Europe (EMA), and other markets. In the US, it bears an FDA-approved label for "the topical treatment of external genital and perianal warts." In Europe, it is available via national agencies with similar indications.

Market penetration remains significant in developed countries, with sales concentrated in clinics, dermatology, and gynecology practices. GSK consistently reports global sales figures in the range of hundreds of millions USD annually, emphasizing its established presence.

What are the key drivers influencing CONDYLOX’s investment prospects?

Primary drivers include:

• Prevalence of HPV-associated warts: An estimated 1-10% of sexually active individuals will develop genital warts at some point. Persistent HPV infection remains a significant public health issue, fueling demand for effective treatments.
• Market saturation: CONDYLOX’s longstanding approval and brand recognition provide a competitive moat, especially in markets with limited patent expirations.
• Pricing and reimbursement policies: Government and insurance coverage in major markets facilitate access and stabilize revenue streams.
• Potential patent expirations: The original patent has expired or is nearing expiration, risking generic competition. GSK has introduced new formulations and combination products to extend lifecycle.
• Regulatory and clinical developments: New formulations (e.g., easier application, reduced treatment duration) could expand market share.

What are the major competitive and technological factors?

• Generic competition: Multiple companies produce podophyllotoxin-based generics, pressuring prices.
• Alternative treatments: Imiquimod, sinecatechins, and laser therapies threaten market share with different efficacy profiles and patient preferences.
• Innovation and R&D pipeline: GSK and competitors evaluate vaccines (e.g., Gardasil) and immunotherapies for HPV-related conditions, potentially reducing reliance on topical treatments.

How do clinical and safety profiles impact investment?

CONDYLOX demonstrates a long-term safety profile consistent with topical treatments. Mild local skin reactions are common but manageable. However, newer treatments with better efficacy or fewer side effects could shift demand.

What are the financial fundamentals and valuation considerations?

• Historical sales data: GSK reports approximately GBP 300 million (~USD 400 million) annual global sales.
• Profit margins: The product experiences high gross margins, typical of established topical pharmaceuticals.
• Growth prospects: Market expansion in emerging economies, where HPV awareness rises, offers upside potential.
• Patent or exclusivity expiry timeline: Key patents have expired or are due to expire within 2-3 years; however, formulation patents may provide temporary exclusivity.
• Investment risks: Price erosion from generics, regulatory changes, and competitive innovation present downside.

What is the outlook for future research, licensing, or market entry?

GSK and other pharmaceutical companies explore combining podophyllotoxin with other agents, developing longer-acting formulations, and leveraging nanotechnology for targeted delivery. Licensing deals or acquisitions could influence the competitive landscape as new entrants seek market share.

What are the regulatory considerations?

Regulatory barriers primarily involve approval of new formulations or delivery mechanisms. Submissions require demonstrating bioequivalence or superior safety/efficacy. Different regions have varying requirements, impacting the speed and cost of bringing innovations to market.

Key Takeaways

• CONDYLOX remains an established treatment for external genital warts with strong brand recognition.
• Market growth relies on HPV prevalence, treatment adherence, and demographic trends.
• Patent expirations threaten revenue streams, but formulation innovations and pipeline developments offer mitigations.
• Competition from generics and alternative therapies remains intense; ongoing R&D is critical.
• Regulatory and reimbursement landscapes influence market access and profitability.

FAQs

1. How does CONDYLOX compare to alternative treatments in efficacy?
CONDYLOX’s efficacy rate ranges widely but is generally comparable to other topical agents like imiquimod. Its advantage lies in simplicity of application and cost, but newer options may offer higher clearance rates or fewer side effects.

2. What is the likelihood of future patent litigation affecting CONDYLOX?
Patent expirations have already occurred or are approaching. Patent litigation risk diminishes but could affect formulations with proprietary delivery systems.

3. Are there emerging therapies that could replace CONDYLOX?
Vaccination against HPV reduces the incidence of new infections but does not treat existing warts. Immunotherapies and laser treatments are more invasive and less aligned with pharmaceutical R&D but could impact sales if they become more accessible.

4. How significant is the market in developing countries for CONDYLOX?
Emerging markets offer growth potential due to increasing awareness and evolving healthcare infrastructure, but price sensitivity and local competition influence margins.

5. What factors could accelerate or delay the product pipeline?
Regulatory approval timelines, clinical trial outcomes, and strategic licensing deals control innovation pace. Delays could result from safety concerns or regulatory hurdles.

---

Sources:

[1] GSK Annual Reports 2022
[2] FDA Label for CONDYLOX (Topical Podophyllotoxin)
[3] European Medicines Agency Summary of Product Characteristics
[4] Market research reports on HPV treatment landscape (e.g., IQVIA, GlobalData)
[5] WHO Global HPV and Genital Warts data